Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc..
Locally advanced basal cell carcinoma (laBCC) represents a rare but possible occurrence in the vast scenario of dermatological diseases. It is well known that most BCC has a pathological activation of the hedgehog pathway, making them susceptible to targeted therapy with selective inhibitors. Sonidegib, approved for the treatment of laBCC on the basis of the results of the basal cell carcinoma outcomes with LDE225 treatment study, demonstrated rapid efficacy and a manageable safety profile. Here, we describe the case of a patient affected by multiple laBCC treated with Sonidegib. The patient experienced an important regression of tumors after only 2 months of therapy, with few side effects. This result confirms the role of Sonidegib as a valid and well-tolerated therapeutic option for laBCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Anti-cancer drugs - 32(2021), 4 vom: 01. Apr., Seite 465-468 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tarantino, Vanessa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0RLU3VTK5M |
|---|
| Anmerkungen: |
Date Completed 07.12.2021 Date Revised 01.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/CAD.0000000000001054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320950522 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320950522 | ||
| 003 | DE-627 | ||
| 005 | 20231225174753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CAD.0000000000001054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320950522 | ||
| 035 | |a (NLM)33534224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tarantino, Vanessa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2021 | ||
| 500 | |a Date Revised 01.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a Locally advanced basal cell carcinoma (laBCC) represents a rare but possible occurrence in the vast scenario of dermatological diseases. It is well known that most BCC has a pathological activation of the hedgehog pathway, making them susceptible to targeted therapy with selective inhibitors. Sonidegib, approved for the treatment of laBCC on the basis of the results of the basal cell carcinoma outcomes with LDE225 treatment study, demonstrated rapid efficacy and a manageable safety profile. Here, we describe the case of a patient affected by multiple laBCC treated with Sonidegib. The patient experienced an important regression of tumors after only 2 months of therapy, with few side effects. This result confirms the role of Sonidegib as a valid and well-tolerated therapeutic option for laBCC | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biphenyl Compounds |2 NLM | |
| 650 | 7 | |a Hedgehog Proteins |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a SHH protein, human |2 NLM | |
| 650 | 7 | |a sonidegib |2 NLM | |
| 650 | 7 | |a 0RLU3VTK5M |2 NLM | |
| 700 | 1 | |a Zavattaro, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Veronese, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Gironi, Laura C |e verfasserin |4 aut | |
| 700 | 1 | |a Savoia, Paola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer drugs |d 1990 |g 32(2021), 4 vom: 01. Apr., Seite 465-468 |w (DE-627)NLM012606693 |x 1473-5741 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:465-468 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CAD.0000000000001054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 4 |b 01 |c 04 |h 465-468 | ||